Experimental antiviral shows 100% efficacy against Ebola in primate trials

Ebola kills with brutal efficiency. In the worst outbreaks, the virus claims nine out of every ten people it infects, spreading fast enough to overwhelm entire regions before containment becomes possible. The 2013-2016 epidemic across West Africa killed more than eleven thousand people, a toll that haunts public health officials still. Now researchers at the University of Texas Medical Branch and Galveston National Laboratory, working with pharmaceutical company Gilead Sciences, say they have found something that might change that calculus: an oral antiviral drug that prevented all deaths in one group of infected primates and most in another.

The drug is called obeldesivir. In the study published March 14 in Science Advances, ten monkeys—five rhesus and five cynomolgus—received the medication for ten days, with the first dose given within twenty-four hours of exposure to Makona, a particularly aggressive Ebola variant. A control group of three monkeys received nothing. The treated rhesus monkeys survived at a one hundred percent rate. The treated cynomolgus monkeys survived at eighty percent. The untreated controls did not survive.

The mechanism is straightforward in principle. Obeldesivir works by blocking the enzyme that allows Ebola to copy itself inside human cells. When viral replication slows, the cascade of inflammation that characterizes the disease—the hemorrhagic fever, the organ failure, the cytokine storms that often prove fatal—never reaches its worst. The treated animals showed dramatically reduced levels of inflammatory molecules in their blood. They also developed antibodies against the virus, suggesting the drug might offer not just survival but actual immunity.

What makes this finding potentially transformative is the form the drug takes. It is a pill. This matters more than it might sound. Every existing Ebola treatment—monoclonal antibodies, remdesivir, the arsenal built over the past decade—requires intravenous injection. In rural areas where Ebola is endemic, where electricity is unreliable and trained medical staff scarce, getting an IV into someone's arm during an outbreak is a logistical nightmare. A pill can be swallowed. It can be stored at room temperature. It can be distributed by health workers with minimal training. Thomas Geisbert, the study's corresponding author and a microbiologist at the Texas medical school, noted that most people prefer tablets to needles anyway. The practical advantage is enormous.

Gilead began studying obeldesivir against COVID-19 in 2022. The Texas team ran the first animal trials for Ebola in early 2023. The results were promising enough to publish, but the researchers are careful about what comes next. Human trials are still required before any regulatory approval. The team wants to understand optimal dosing, how long treatment should last, and—crucially—how long after exposure the drug can still prevent viral replication. If that window is wide enough, obeldesivir could become a preventive tool, something health workers and at-risk populations could take after contact with a confirmed case, the way people at risk for HIV take antiretroviral drugs now.

Geisbert also raised a broader possibility: obeldesivir showed activity against other filoviruses beyond Ebola, and it was originally developed for SARS-CoV-2. The drug might work against multiple viral threats. In a world where pandemics arrive without warning, a broad-spectrum antiviral that is easy to manufacture, distribute, and take could be more valuable than any single-disease cure. The next phase will tell whether the promise holds in human bodies, where biology is always more complicated than it appears in the lab.